Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

Opus Genetics (NASDAQ:IRD) outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its funding strategy during an investor panel featuring Chief Executive Officer Dr. George Magrath and Chief Financia